Self-funded, non-profit medical research organisation and charity LifeArc has announced today that it is to launch the Rare Disease Translational Challenge, which will inv
My training as a clinical ophthalmologist and retinal surgeon led me to a career dedicated to developing better therapies for people suffering from debilitating eye diseases and the many co
To have any impact, patient engagement needs to start with the drug development pathway, not at the point of licensing. That’s especially true in the rare disease space, where the unme
Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market.